Acceder

Farmas USA

136K respuestas
Farmas USA
85 suscriptores
Farmas USA
Página
5.019 / 17.032
#40147

Re: Farmas USA

3.30 + 10.%
Dendreon Announces Preliminary Fourth Quarter 2013 Revenues
SEATTLE --(BUSINESS WIRE)-- Dendreon Corporation (NASDAQ: DNDN) today announced preliminary revenues for the fourth quarter ended December 31, 2013 . Net product revenue for the quarter is expected to be approximately $74.8 million , up 10.1% on a sequential basis.

Recent Highlights:

Business has continued to strengthen
Community oncology grew 19% overall quarter over quarter Community urology grew 2% overall quarter over quarter Community accounts represent 72% of total sales Academic grew 5% quarter over quarter Continued large account growth
100 large accounts in Q4, up from 94 in Q3, 85 in Q2 and 54 in Q1 Continued to generate new physician interest in PROVENGE® (sipuleucel-T)
Added 31 net new accounts in Q4 Continued progress on restructuring and cost reduction plan to accelerate the path to profitability; continue to expect net benefits to begin to be realized as early as Q1 2014 Advancing automation efforts
Recently conducted a constructive meeting with the FDA regarding automation of the PROVENGE manufacturing process; Agency expressed its support for this effort Cash on hand of approximately $199 million as of December 31, 2013 Continue to develop clinical data in the active cellular immunotherapy space Plans to present data from ongoing immuno-oncology trials, which further elucidate the product potency and mechanism of PROVENGE, and surrounding investigational compound DN24-02, at ASCO-GU later this month

#40149

Re: Farmas USA

RNN .. sigue su marcha imparable.

#40150

Re: Farmas USA

No me gusta que queden espacios sin llenar "gap".
DVAX

#40151

Re: Farmas USA

MACK

El 15 (miercoles) participa en la conferencia JPM14 y el 16 (jueves) libera datos del MM-111 en el ASCO GI de San Francisco.

http://investors.merrimackpharma.com/releasedetail.cfm?ReleaseID=818827

ROSG

Otra deshauciada que despierta. +34%

BAXS

Se veia venir, y yo fuera :-(

CVM

Hoy parece que da entrada. El miedo es el poco cash.

Te puede interesar...
  1. Primeras dudas sobre la 'Trumponomics', ¿corrección o toma de beneficios?